PA-824
PA-824 is a pharmaceutical drug with 13 clinical trials. Historical success rate of 92.3%.
Success Metrics
Based on 12 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
5
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
92.3%
12 of 13 finished
7.7%
1 ended early
0
trials recruiting
13
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function
A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB
Pretomanid in Adults With Hepatic Impairment
Assessing PA-824 for Tuberculosis (the APT Trial)
Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin
Clinical Trials (13)
Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function
A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB
Pretomanid in Adults With Hepatic Impairment
Assessing PA-824 for Tuberculosis (the APT Trial)
Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010)
Evaluation of the Pharmacokinetic Interaction Between PA-824 and Midazolam
A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.
Shortening Treatment by Advancing Novel Drugs
A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects.
PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)
Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers
All 13 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 13